Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Sold by Krilogy Financial LLC

Krilogy Financial LLC trimmed its holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 14.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 94,952 shares of the company’s stock after selling 15,568 shares during the quarter. Krilogy Financial LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $922,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Atria Investments Inc acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the third quarter valued at approximately $122,000. Centaurus Financial Inc. acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the second quarter valued at approximately $146,000. Rockefeller Capital Management L.P. acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the third quarter valued at approximately $205,000. James J. Burns & Company LLC boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 6.0% in the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after acquiring an additional 1,038 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the second quarter valued at approximately $590,000. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Trading Down 0.1 %

GNOM stock opened at $9.60 on Monday. The company has a market capitalization of $66.91 million, a P/E ratio of -4.10 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a twelve month low of $9.50 and a twelve month high of $12.53. The business has a 50 day simple moving average of $10.17 and a 200-day simple moving average of $10.76.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.